PXD014718

PXD014718 is an original dataset announced via ProteomeXchange.

Title	Synthetic polyclonal-derived CDR peptides as innovative strategy in glaucoma therapy
Description	The pathogenesis of glaucoma is strongly associated with the occurrence of autoimmune-mediated loss of retinal ganglion cells (RGCs) and recently it was proven that specific antibody-derived signature peptides are significantly differentially expressed in sera of primary open angle glaucoma patients (POAG) compared to healthy controls. Synthetic antibody-derived peptides are known since several years to modulate various effector functions of the immune system and to act as antimicrobial or antiviral molecules. The present study shows for the first time that polyclonal-derived complementarity-determining regions (CDRs) significantly increased the survival rate of RGCs in an ex vivo glaucoma model (P=0.013) by using immunohistochemical staining techniques. Affinity capture experiments verified serine protease HTRA2 (mitochondrial) as high-confident retinal epitope target of CDR1 sequence motive ASGYTFTNYGLSWVR. Quantitative proteomic analysis of the CDR-treated retinal explants revealed increased expression of various anti-apoptotic and anti-oxidative proteins (e.g. VDAC2 and TXN) compared to untreated controls (P<0.05) and decreased expression levels of cellular stress response markers (e.g. HSPE1 and HSP90AA1) were observed. Mitochondrial dysfunction, protein ubiquitination pathway and oxidative phosphorylation were annotated as the most significantly affected signaling pathways and can possibly be traced back to the CDR-induced inhibition or modulation of the master regulator HTRA2. These findings emphasize the great potential of synthetic polyclonal-derived CDR peptides as therapeutic agents in future glaucoma therapy and provide an excellent basis for affinity-based biomarker discovery purposes.
HostingRepository	PRIDE
AnnounceDate	2019-08-15
AnnouncementXML	Submission_2019-08-26_00:05:44.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Carsten Schmelter
SpeciesList	scientific name: Sus scrofa domesticus (domestic pig); NCBI TaxID: 9825; scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	acetylated residue; monohydroxylated residue; iodoacetamide derivatized residue
Instrument	LTQ Orbitrap

Revision	Datetime	Status	ChangeLog Entry
0	2019-07-23 06:14:05	ID requested
1	2019-08-15 03:49:29	announced
⏵ 2	2019-08-26 00:05:45	announced	Updated publication reference for PubMed record(s): 31443184.

Schmelter C, Fomo KN, Perumal N, Manicam C, Bell K, Pfeiffer N, Grus FH, Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy. J Clin Med, 8(8):(2019) [pubmed]

submitter keyword: Glaucoma

Autoimmunity

Synthetic CDR peptides

Neuroprotection

HTRA2

Sus scrofa domesticus

Carsten Schmelter
contact affiliation	Experimental and Translational Ophthalmology, University Medical Care Center in Mainz, Germany
contact email	cschmelter@eye-research.org
lab head
Carsten Schmelter
contact affiliation	Universitätsmedizin Mainz
contact email	cschmelter@eye-research.org
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/08/PXD014718

PRIDE project URI

• PRIDE
  1. PXD014718
     1. Label: PRIDE project
     2. Name: Synthetic polyclonal-derived CDR peptides as innovative strategy in glaucoma therapy